BioCentury on BioBusiness,
Product Discovery & Development
How AZ's olaparib combinations may produce large PFS gains in ovarian cancer
Related tables, figures and sidebars
Sum of PARPs
Monday, June 9, 2014
Data for olaparib plus cediranib presented at the American
Society of Clinical Oncology meeting show the ovarian cancer therapies may
be able to achieve unprecedented gains in progression-free survival when used
in combination. Whether the combination catches on will depend on how well
physicians can manage the regimen's increased toxicity over olaparib
monotherapy, and whether patients are willing to undergo the higher side effect
In combination, AstraZeneca
plc's compounds led to an eight-month PFS benefit over olaparib
monotherapy, according to interim data from a 90-patient Phase II trial in
women with recurrent platinum-sensitive ovarian cancer. The National
Cancer Institute sponsored the study.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]